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Abstract
Objective: To comprehensively examine the associations of serum uric acid (SUA) with central and peripheral arterial
stiffness in Chinese adults, and particularly assess the interactions between SUA and other cardiometabolic risk factors.
Methods: The study included 3,772 Chinese men and women with carotid radial pulse wave velocity (crPWV), carotid
femoral PWV (cfPWV), carotid artery dorsalis pedis PWV (cdPWV) and SUA measured.
Results: After adjustment for age, sex, and BMI, the levels of SUA were significantly associated with increasing trend of
cfPWV, crPWV and cdPWV (P for trend ,0.0001). Further adjustment for heart rate (HR), blood pressure (BP) and lipids
attenuated the associations with crPWV and cdPWV to be non-significant (P=0.1, P=0.099 respectively), but the association
between SUV and cfPWV remained significant (P=0.004). We found significant interactions between SUA and HR or BP in
relation to cfPWV (P for interaction=0.03, 0.003 respectively). The associations between SUA and cfPWV were more evident
among individuals with higher HR or normal BP than those with lower HR or hypertension.
Conclusions: SUA was associated with elevated aortic arterial stiffness in Chinese adults, independent of conventional
cardiovascular risk factors. BP and HR might modify the deleterious effects of SUA.
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Introduction
Serum uric acid (SUA) is a final enzymatic product of purine
metabolism in humans. In clinical and epidemiological studies,
SUA has been related to the risk of hypertension [1–3],
atherosclerosis [4] and cardiovascular diseases (CVDs) [5,6]. The
adverse effects of SUA may occur at early stage of atherosclerosis
[7,8]. Pulse wave velocity (PWV) is a gold standard for assessing
arterial stiffness and widely used indicator for early atherosclerosis
[9,10], and PWVs at different sites may reflect the atherosclerotic
alterations at central (e.g. cfPWV) or peripheral arteries (e.g.
cdPWV and crPWV). Few studies have comprehensively com-
pared the effects of circulating SUA on these various measures.
In addition, it has been documented that both blood SUA levels
and arterial stiffness are tightly related to other cardiometabolic
risk factors such as high heart rate (HR) or blood pressure (BP)
[2,3,11,12]. However, few studies have examined the potential
interactions between SUA and those factors. It remains to be
determined whether other cardiometabolic risk factors may
modify the cardiovascular effects of SUA.
In the present study of a large sample of Chinese adults, we
sought to comprehensively evaluate the effects of SUA on
peripheral and central arterial stiffness. We particularly assessed
whether blood pressure, heart rate, and other cardiometabolic risk
factors may modify the relation between SUA and arterial stiffness.
Methods
1. Study Population
In the Cardiometabolic Risk in Chinese (CRC) Study, we
performed a community-based health examination survey for
subjects (18–93 y) who were randomly selected from residents
PLOS ONE | www.plosone.org 1 December 2012 | Volume 7 | Issue 12 | e51101living in the urban area of Xuzhou, China, in 2009. Written
consents were obtained from all the participants. The study was
reviewed and approved by the ethics committee of the Central
Hospital of Xuzhou, Affiliated Hospital of Medical School of
Southeast University, China. For the present study, we included
adult men and women ($18 y) who were successfully measured
for PWVs, BP, Body mass index (BMI), HR, SUA and other
metabolic markers. The exclusion criteria included the history of
vascular disease, diabetes mellitus, or hyperlipidemia which was
being treated with medication, and renal failure (GFR reduced to
10,20% and serum creatinine elevated to 451,707 umol/L)
[13]. In addition, we excluded people who did not undergo PWV
determination or omitted blood sampling. In total 3,772 men and
women were included in the final analyses. There was not
significant difference in basic characteristics such as age, educa-
tion, and anthropometrics between individuals included in the
analyses and those who were excluded.
2. Assessment of PWVs
All measurements were performed in a quiet room with
controlled ambient temperature. The cfPWV was measured in
the supine position after 5 min of bed rest using an automatic
waveform analyzer (Complior System, Artech-Medical corp.
French), the pulse wave of the carotid and femoral arteries was
analyzed, estimating the delay with respect to the ECG wave and
calculating the PWV. cdPWV and crPWV were obtained in a
similar way, with the pulse wave being measured simultaneously in
the right radial, dorsum of foot and right carotid arteries. 16
consecutive electrocardiogram gated waveforms were obtained
and removed the three maximum and three minimum. For
analysis, we averaged 10 waveforms. PWV was based on the
distance/time ratio (meters/second), was calculated as the path
length divided by the transit time and expressed as m/s [14].
3. Assessment of Biomarkers and covariates
All the participants were measured biomarkers. Venous blood
sample was drawn from all subjects after an overnight fast (8–
12 h). After blood was drawn, samples were allowed to clot at
room temperature for 1–3 h and serum was separated. Immedi-
ately after clotting, serum was separated by centrifugation for
15 min at 3000 r.p.m. Fasting blood samples were collected for
measurement of glucose, SUA, total cholesterol (TC), triglyceride
(TG), high-density lipoprotein cholesterol (HDL-C) and low-
density lipoprotein cholesterol (LDL-C). All biochemical assays
were determined enzymatic ally on an auto analyzer (Type 7600,
Hitachi Ltd, and Tokyo, Japan). Height was measured to the
nearest 0.5 cm without shoes and body weight was measured to
the nearest 100 grams without shoes. BMI was calculated as
weight (in kilograms) divided by height (in meters) squared. BP was
measured after the subject had rested for at least 5 minutes with a
mercury manometer by doctors. The mean arterial pressure
(MAP) was calculated as 2/3(Diastolic blood pressure,DBP)+1/
3(Systolic blood pressure,SBP). Three measurements, 60 seconds
apart, were taken. The mean of the three measurements was used
for analysis. Information of education level, income smoking status
and alcohol consumption was collected using a questionnaire.
4. Statistical Analysis
The relations between SUA levels (in quartiles) and PWVs were
examined using general linear regression models, adjusting for
covariates including age, sex, BMI, HR, fasting glucose, lipid
profiles and BP. SUA and TG levels were log-transformed to
improve normal distribution before analysis. The interactions
between SUA and other cardiometabolic risk factors were assessed
by introduction of cross-product term in the regression models. All
reported P values are two tailed. Variables with P values of ,0.05
were considered statistically significant. Data management and
statistical analysis were conducted using SAS statistical software
(version 9.1; SAS Institute, Inc., Cary, NC, USA).
Results
1. The characteristics of the study participants by SUA
levels
The average age of study population was 45.4 years and was
represented by 63.3% of men. Table 1 shows the characteristics
of the study participants according to SUA levels (in quartiles).
BMI, waist circumference, BP, glucose, insulin, TG and LDL-C
showed statistically significant differences between SUA groups,
with an increasing trend as the concentration of SUA increased,
except for HDL-C that showed a decreasing trend.
2. Association between SUA and markers of central and
peripheral arterial stiffness
Table 2 displays the associations of PWVs with SUA in
quartile. After adjustment for age, sex and BMI, the levels of SUA
were significantly associated with an increasing trend of cfPWV,
crPWV and cdPWV in a dose-dependent pattern (P for trend
,0.0001). Further adjustment for HR, fasting glucose and lipids
did not significantly change the associations. However, further
addition of blood pressure in the models attenuated the
associations with crPWV and cdPWV to be not significant
(P=0.1, P=0.099 respectively); while the association between
SUV and cfPWV remained significant (P=0.004). Additional
adjustment of education level, income, smoking and alcohol
consumption did not appreciably change the results.
3. Stratified associations by cardiometabolic risk factors
We found significant interaction between age and SUA level in
relation to cfPWV (P for interaction ,0.001). (Table 3) The
associations were significant in groups of 40 to 59 y (P=0.03) and
$60 y (P=0.02), but not significant among those of ,40 y
(P=0.18). There was no significant interactions of SUA with sex
and BMI in relation to cfPWV.
We also examined the associations between SUA and cfPWV in
different HR categories: #65, 65–75 and $75 bpm (Figure 1).
After adjustment for age, sex, BMI, fasting glucose, lipids and BP,
we found that the association between SUA and cfPWV was
different in three HR groups (P for interaction=0.03). The
associations were stronger in individuals with HR of 65–75 bpm
(P=0.007) and $75 bpm (P=0.007) than those with
HR,65 bpm (P=0.11). In addition, we found significant
interaction between hypertension status and SUA level in relation
to cfPWV, adjusted for age, sex, BMI, fasting glucose, lipids and
HR (P for interaction=0.003). The associations between SUA and
cfPWV were significant (P,0.0001) among those with normal
blood pressure, but not significant among those with hypertension
(Figure 2).
Discussion
In the present study of a large sample of Chinese adults, we
found that SUA levels were significantly related to central arterial
stiffness independent of conventional risk factors, such as sex,
BMI, lipids, glucose metabolism. SUA levels were not associated
with peripheral arterial stiffness, measured by crPWV and
cdPWV. Moreover, we found significant interactions between
SUA and HR or BP in relation to cfPWV.
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SUA in quartiles(umol/L) P
Variables Q1 (#238,N=941)
Q2 (238–294.4,
N=943) Q3 (294.4–348.9, N=946) Q4 ($348.9,N=942) for trend
cfPWV(m/s) 9.8360.05 10.3960.06 10.7560.06 11.060.06 0.009
cdPWV(m/s) 8.8760.05 9.5660.05 9.8560.06 10.160.05 0.23
cr PWV(m/s) 9.5960.05 10.2760.05 10.6860.06 11.060.06 0.003
Age, years 45.2612.1 44.8611.4 45.1611.7 45.7612.4 0.33
Men, % 63.3 63.3 63.3 63.4 1.00
Body mass index, kg/m
2 23.560.1 24.160.1 24.460.1 25.860.1 ,0.0001
Waist circumference, cm 83.260.3 84.460.3 85.760.3 89.160.3 ,0.0001
Systolic blood pressure,
mmHg
121.260.5 122.560.5 123.660.5 127.060.5 ,0.0001
Diastolic blood pressure,
mmHg
77.360.4 78.060.4 79.860.4 82.160.4 ,0.0001
Fasting glucose, mmol/L 4.860.04 5.060.04 5.160.04 5.260.04 0.02
Fasting insulin (IU/ml) 7.560.14 8.460.15 9.060.17 11.260.24 ,0.0001
2 h OGTT, mmol/L 7.4860.10 7.1560.10 7.2960.10 7.7260.11 0.03
Triglyceride, mmol/L 1.2660.05 1.4860.05 1.6560.05 2.1860.05 ,0.0001
LDL-C (mmol/l) 2.860.03 2.960.03 3.060.03 3.160.03 ,0.0001
HDL-C, mmol/L 1.3060.01 1.2760.01 1.2560.01 1.2060.01 ,0.0001
Abbreviations: OGTT, oral glucose tolerance test; HDL-C, high density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. Data are age and sex adjusted
mean 6 standard error.
Linear regression model was used to test trend for continuous variables; x
2 test was used for the categorical variables.
doi:10.1371/journal.pone.0051101.t001
Table 2. Associations of SUA with central and peripheral arterial stiffness.
SUA in quartiles P
Models Q1 Q2 Q3 Q4 for trend
cf_PWV
Crude 10.39 (0.06) 10.44 (0.06) 10.62 (0.06) 10.82 (0.06) ,.0001
Age and sex adjusted 10.39 (0.05) 10.46 (0.05) 10.63 (0.05) 10.79 (0.05) ,.0001
Further adjusted for BMI 10.41 (0.06) 10.47 (0.05) 10.63 (0.05) 10.80 (0.06) ,.0001
Further adjusted for fasting glucose, lipid profiles
and heart rate
10.48 (0.06) 10.53 (0.06) 10.63 (0.06) 10.76 (0.06) 0.0006
Further adjusted for blood pressure 10.48 (0.05) 10.51 (0.05) 10.65 (0.05) 10.72 (0.05) 0.004
cd_PWV
Crude 9.40 (0.05) 9.50 (0.05) 9.64 (0.05) 9.78 (0.05) ,.0001
Age and sex adjusted 9.40 (0.05) 9.51 (0.05) 9.64 (0.05) 9.77 (0.05) ,.0001
Further adjusted for BMI 9.46 (0.05) 9.52 (0.05) 9.64 (0.05) 9.71 (0.05) ,.0001
Further adjusted for fasting glucose, lipid profiles
and heart rate
9.54 (0.05) 9.54 (0.05) 9.62 (0.05) 9.68 (0.05) 0.03
Further adjusted for blood pressure 9.56 (0.05) 9.54 (0.05) 9.62 (0.05) 9.65 (0.05) 0.099
cr_PWV
Crude 10.12 (0.05) 10.29 (0.05) 10.40 (0.05) 10.39 (0.05) ,.0001
Age and sex adjusted 10.12 (0.05) 10.28 (0.05) 10.40 (0.05) 10.39 (0.05) ,.0001
Further adjusted for BMI 10.13 (0.05) 10.28 (0.05) 10.40 (0.05) 10.39 (0.05) ,.0001
Further adjusted for fasting glucose, lipid profiles
and heart rate
10.20 (0.05) 10.33 (0.05) 10.40 (0.05) 10.38 (0.05) 0.014
Further adjusted for blood pressure 10.23 (0.05) 10.34 (0.05) 10.38 (0.05) 10.35 (0.05) 0.10
PWVs are presented as mean (standard error).
doi:10.1371/journal.pone.0051101.t002
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associated with cardiovascular disease [15,16], and the detrimental
effects of high SUA might occur at early stage of atheroclerosis
[7,8]. In a recent cross-sectional study, it was found that SUA was
independently related to brachial ankle PWV (baPWV) in She
ethnic minority of China [17]. However, it is not clear whether
SUA levels specifically affect central or peripheral arterial stiffness
because baPWV may be influenced by both sites [18]. Our results
indicate that high SUA more likely affect central arterial stiffness;
while its effects on peripheral arterial stiffness are modest. Notably,
in the Framingham Heart Study, one standard deviation (SD)
increment in arterial stiffness, as measured by cfPWV, was
associated with a 48% increase in arterial disease risk, indepen-
dently of conventional risk factors [19].
Intriguingly, we found the association between SUA and
cfPWV was stronger among adults with higher HR ($65). Several
cohort studies have demonstrated that increased HR at rest is a
significant risk factor for CVD and is a marker of new onset of
atherosclerosis even in apparently healthy individuals [20,21].
Evidence has also shown that elevated HR is directly associated
with risk of developing hypertension and metabolic syndrome, and
is a potent predictor of cardiovascular mortality [22]. A recent
prospective study found a synergistic role of high baseline HR and
changes in HR during the follow-up period in accelerating
Table 3. Stratified associations between SUA and cfPWV by sex, age and BMI.
SUA in quartiles P for P for
Q1 Q2 Q3 Q4 trend interaction
Age
,40 y; N=1070 10.00 (0.09) 9.95 (0.08) 10.07 (0.08) 10.13 (0.08) 0.18 ,0.001
40 to 59 y; N=2347 10.41 (0.06) 10.44 (0.06) 10.53 (0.06) 10.57 (0.06) 0.03
$60 y; N=355 12.52 (0.33) 13.00 (0.35) 13.56 (0.32) 13.54 (0.31) 0.02
Sex
Women, N=1283 9.79 (0.08) 9.79 (0.08) 9.96 (0.08) 10.0 (0.08) 0.04 0.65
Men, N=2389 10.86 (0.07) 10.91 (0.07) 11.03 (0.07) 11.09 (0.07) 0.01
BMI
,23 kg/m2; N=1350 10.07 (0.08) 10.44 (0.08) 10.39 (0.09) 10.40 (0.12) 0.008 0.53
23 to 24.9 kg/m
2; N=895 10.59 (0.11) 10.37 (0.10) 10.62 (0.10) 10.56 (0.11) 0.70
$25 kg/m
2; N=1527 10.92 (0.10) 10.62 (0.09) 10.89 (0.08) 10.98 (0.07) 0.11
Analyses were adjusted for age, sex, BMI, total cholesterol, triglyceride, HDL-C, LDL-C, blood pressure, heart rate and fasting glucose but not the strata variable. cfPWV is
presented as mean (standard error).
doi:10.1371/journal.pone.0051101.t003
Figure 1. Interaction between SUA and HR in relation to cfPWV. The predicted cfPWV by log-transformed SUA in different HR categories:
#65, 65–75 and $75 bpm are presented. Analysis was adjusted for age, sex, BMI, fasting glucose, lipids and BP.
doi:10.1371/journal.pone.0051101.g001
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suggest that high SUA and high HR may synergistically affect
central arterial stiffness.
Another interesting finding is that, the adverse effects of SUA on
central arterial stiffness appeared more evident in people with
normal blood pressure than those with hypertension. Notably, on
average cfPWV was much higher and its variance was smaller in
individuals with hypertension than those with normal blood
pressure (Figure 2). Therefore, it is not surprising a null association
was observed between SUA and cfPWV in hypertensive patients.
Recent clinical evidence and experimental studies showed that
SUA levels contribute to incident hypertension and prehyperten-
tion [2,3,23,24]. One prospective study showed that inflammatory
and adiponectin-mediated proatherogenic activation are interre-
lated and interact leading to a significant increase of arterial
stiffness in essential hypertensive patients [25]. Our findings
suggest that high SUA levels may play a more important role in
arterial stiffness before the development of hypertension. This
finding might have important clinical implications for prevention
and intervention of cardiovascular risk at early stage.
Our data showed a stronger effect of SUA on central arterial
stiffness in older population. Shen et al. reported that cfPWV
increased at the early stage of carotid artery atherosclerosis in
elderly patients, compared to younger subjects [26]. Elevated SUA
experimentally stimulates renal vasoconstriction and activation of
the renin-angiotensin system. Senior age is associated with
activation of the renin–angiotensin system and with renal
vasoconstriction [27]. Also increased SUA levels are accompanied
by a state of pronounced inflammatory activation and hypoadi-
ponectinemia that significantly impairs the arterial stiffness
accelerating the vascular ageing process [28]. Our results suggest
that older individuals may be more sensitive to the detrimental
effects of high SUA on atherosclerosis.
The sample size of the present study is large, which ensures
sufficient power to detect the moderate effects of SUA on arterial
stiffness and interactions with other cardiometabolic risk factors.
However, several limitations of this study warrant consideration.
Our study is cross-sectional in design. Therefore, a causal relation
between SUA and arterial stiffness could not be derived. We have
carefully adjusted for the potential confounding in the analyses.
However, in our study samples, we did not collection information
of dietary intake and the lifestyle information is not incomplete.
Therefore, it is still possible the residual confounding of these
unmeasured variables might influence the associations. In
addition, the study was performed in a Chinese population.
Further studies in other populations of different ethnicities are
warranted to verify our findings.
Conclusion
In conclusion, in Chinese adults we found that SUA was
associated with elevated aortic arterial stiffness, independent of
conventional cardiovascular risk factors. BP and HR might modify
the deleterious effects of SUA. Our data lend support of the role of
SUA in development of cardiovascular disease at early stage; and
suggest to jointly consider the interactions of SUA with other risk
factors in prevention of heart disease.
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